🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  2. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  3. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  4. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  5. ONX-0801

    United Therapeutics Europe Ltd

    Solid Tumours

    phase 1 small molecule completed

    1 trial

  6. Octreotide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Enterocutaneous Fistulas

    phase 1 small molecule completed

    1 trial

  7. Ondansetron 8 mg ODFS without water

    Aquestive Therapeutics

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  8. Outpatient MST/OPTION-A

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 other completed

    1 trial

  9. PEGylated recombinant candida urate oxidase

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  10. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  11. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

  12. Palbociclib + Taselisib / Pictilisib

    United Therapeutics Europe Ltd

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  13. Pegylated Recombinant Candida Utilis Uricase for Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  14. Pembrolizumab

    United Therapeutics Europe Ltd

    Thoracic Tumours

    phase 1 small molecule completed

    1 trial

  15. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  16. Pevonedistat

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  17. Pharmacokinetic study of colistimethate sodium

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

  18. Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease

    Disc Medicine

    Nontuberculous mycobacterial disease

    phase 1 other active

    1 trial

  19. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  20. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  21. Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  22. Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  23. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  24. Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources